MPML yields 2000000.00% · ABBV yields 3.06%● Live data
📍 MPML pulled ahead of the other in Year 1
Combined, MPML + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MPML + ABBV for your $10,000?
MPM Technologies, Inc., through its subsidiaries, designs, engineers, supplies, and services air pollution control systems for environmental and industrial companies in the United States and internationally. The company provides air pollution control systems by utilizing wet and dry scrubbers, wet electrostatic precipitators, and venturi absorbers that control air pollution. It also involves in the development and commercialization of Skygas, a waste-to-energy process that converts solid and semi-solid wastes into a clean-burning medium BTU gas that can be used for steam production for electric power generation, as well as for downstream conversion into chemicals. The company's Skygas technology is used for the disposal and gasification of carbonaceous wastes, such as municipal solid waste, municipal sewage sludge, pulp and paper mill sludge, auto fluff, medical waste, and used tires. It has a strategic alliance with Foton Technologies, LLC to develop projects to produce power, chemicals, and liquid fuels utilizing Skygas gasification-derived syngas. The company was formerly known as Montana Precision Mining, Ltd. and changed its name to MPM Technologies, Inc. in August 1995. MPM Technologies, Inc. was founded in 1983 and is based in Spokane Valley, Washington. MPM Technologies, Inc. operates as a subsidiary of Carbon Cycle Investments, LLC.
Full MPML Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.